Background {#Sec1}
==========

Abnormal uterine bleeding (AUB), traditionally defined as uterine bleeding that is abnormal in volume, regularity, and/or timing \[[@CR1]\] is common and affects 14--25% of women of reproductive age \[[@CR2]--[@CR4]\]. In the UK, approximately 1 million women seek medical advice for AUB every year, mostly in general practice \[[@CR5], [@CR6]\] and even though most cases could potentially be managed exclusively in primary care \[[@CR7], [@CR8]\], AUB is the fourth most common reason for referral to UK gynaecological services \[[@CR6], [@CR9], [@CR10]\]. AUB has a major impact on quality of life \[[@CR7]\], leads to 3.5 million days of work absence \[[@CR11]\], and generates significant health care costs. Hospital referrals and hysterectomies are the major components of the £65 million/year treatment costs for AUB \[[@CR10]\].

Most cases of AUB are benign and amenable to office-based treatments \[[@CR12], [@CR13]\]. However, patients often present with a myriad of symptoms, and their assessment requires training and expertise \[[@CR13], [@CR14]\]. The causes of AUB can be summarised using the PALM-COEIN acronym: polyps, adenomyosis, leiomyoma/fibroids, malignancy (and hyperplasia), coagulopathy, ovulatory disorders, endometrial, iatrogenic, and not otherwise classified \[[@CR1]\].

Some patients who present with AUB will have endometrial hyperplasia or cancer which is the commonest gynaecological malignancy in the Western world. Even though the incidence rises after menopause, it can occur at all ages and 7% of cases are under 50 \[[@CR15], [@CR16]\]. This percentage seems to be rising with increasing prevalence of obesity and diabetes \[[@CR17], [@CR18]\].

In the UK, women with AUB who are deemed at high risk of endometrial cancer such as those with postmenopausal bleeding (PMB) or family history of gynaecological neoplasms, should be referred to secondary care \[[@CR19]\]. For low-risk premenopausal women the guidance is not as clear. Although urgent referral is not required \[[@CR20]\], national guidelines recommend that endometrial sampling (ES) should be performed in women over 40--45 years to exclude cancer \[[@CR21], [@CR22]\], but they do not specify whether ES should be performed in primary or secondary care \[[@CR22]\].

In the UK, ES for AUB patients has not been traditionally undertaken in primary care. For many years, the standard management was dilation and curettage (D&C) in hospital under general anaesthesia \[[@CR23]--[@CR25]\]. However, the need for admission and the risks of perforation and haemorrhage made D&C unpopular \[[@CR23], [@CR25]\] and various ES devices were developed such as the Novak (a silastic cannula with a bevelled lateral opening \[[@CR26]\]), the Tis-u-Trap (a plastic curette with suction \[[@CR27]\]), the Vabra Aspirator (a stainless steel cannula connected to a vacuum pump \[[@CR28]\]), the Endorette (a plastic cannula with multiple openings \[[@CR29]\]), the Tao Brush (a sheath brush device \[[@CR30]\]), the Cytospat (a polypropylene cannula with a rhomboid head \[[@CR31]\]), the Accurette (a quadrilateral-shaped curette with four cutting edges \[[@CR32]\]) and the Pipelle, the most widely used device in the UK (a flexible plastic tube with a distal circular port \[[@CR27]\]).

We conducted a systematic review of the literature to identify existing evidence about the effectiveness of Pipelle compared with other ES techniques for assessing low-risk women with AUB which could inform the development of new care pathways in primary care.

Why this study was necessary {#Sec2}
----------------------------

Endometrial sampling is thought to be a safe and effective method for histological assessment of the endometrium. It is used as an alternative to the more invasive method of D&C. This is the first review to focus on AUB in low-risk pre- and perimenopausal women. We conclude that ES is a valuable tool in the assessment of these patients and that Pipelle is the best outpatient device available. The evidence supports the use of Pipelle in the outpatient setting but more research is required to assess its impact if introduced as routine management of AUB in the community.

Methods {#Sec3}
=======

Literature search {#Sec4}
-----------------

We used the PICO approach to develop a systematic search strategy \[[@CR33]\]. We searched MEDLINE via OvidSP, Scopus, and Web of Science. For Medline, key concepts were identified (endometrial hyperplasia/cancer, abnormal uterine bleeding, endometrial sampling), a list of synonyms was generated for each concept and these lists were used to identify MeSH terms for the search (Additional file [1](#MOESM1){ref-type="media"}). Similar search strategies were used for Scopus and Web of Science (Additional file [1](#MOESM1){ref-type="media"}), always limited to papers from 1984 (when Pipelle was first introduced \[[@CR34]\]) to 2016, written in English and involving humans.

We included papers investigating ES in women with AUB. We also considered studies in patients with known cancer; although these studies do not inform the indication of ES in primary care, they were an important source to evaluate test performance. We included review articles and opinion pieces. We excluded papers exclusively analysing postmenopausal patients, papers where the indication was assessment of fertility or recurrent miscarriage and papers where ES was assisted by hysteroscopy (unless this was used as a comparator to blind ES).

The initial search generated 173 results for Medline, 240 for Scopus, and 221 for Web of Science, totalling 634 search hits across all databases, 317 of which were excluded for duplication. The remaining 317 articles were assessed for inclusion using the titles and abstracts. The assessment was independently repeated by a second reviewer and a consensus was reached. After this process, 257 papers were excluded and the full text of 60 papers were read. Twenty-two further papers were excluded while another 22 papers were added from reference search, giving a final list of 60 papers. This selection included 16 randomized controlled trials (RCT), 26 prospective studies, 6 retrospective studies, 5 reviews, 2 meta-analyses, 1 survey, and 4 brief communications and letters to the editor, which were included in the final analysis providing data over 7300 women (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flow diagram for study selection

### Bias risk assessment {#Sec5}

The quality of the RCTs was assessed using the standard Cochrane Risk of Bias tool \[[@CR35]\], and the quality of observational studies was analysed with the modified Agency for Healthcare Research and Quality (AHRQ) quality assessment criteria \[[@CR36]\].

Results {#Sec6}
=======

Risk of Bias / quality of studies {#Sec7}
---------------------------------

The overall quality of the RCTs was poor (*n* = 4) to moderate (*n* = 12), no high quality studies were identified. For observational studies, the risk of bias ranged from 31 to 79% with a mean weighted score 52.8% SD ± 11.8% which again suggests overall moderate quality \[[@CR37]\]. See additional online content for tabulated assessments of individual studies (Additional file [2](#MOESM2){ref-type="media"}: TableS1 and 2, Additional file [2](#MOESM2){ref-type="media"}).

Five themes {#Sec8}
-----------

We identified five major themes in the literature: (1) sample adequacy (defined as enough tissue to be analysed by pathologists \[[@CR38]\]); (2) test performance when compared with hysterectomy and D&C; (3) acceptability by the patient in terms of pain experienced during sampling; (4) the costs of taking outpatient endometrial biopsies; and (5) the barriers and complications of performing office ES.

All studies, except for one, were carried out in specialised outpatient gynaecology clinics or hospital services (secondary care) \[[@CR39]\]. Only one study looked exclusively at premenopausal women \[[@CR40]\]. The rest reported on cohorts of both pre- and post-menopausal women or they did not present results based on menopausal status. Most studies included women with symptomatic AUB and no risk of endometrial carcinoma. However, five studies targeted women with endometrial cancer to correlate pre-operative Pipelle with the hysterectomy histopathology \[[@CR41]--[@CR45]\]. Studies are summarised in Table [1](#Tab1){ref-type="table"}.Table 1Comparison of the RCTs, prospective and retrospective studies included in this literature review. Papers have been grouped by intervention/ comparatorStudyType of studyAge of participants (mean ± SD)Intervention (n) vs Comparator (n)OutcomePainCostPipelle versus D&C +/− Hysterectomy\[[@CR23]\] Rauf et al. Pakistan 2014RCT46.3 ± 4.45Pipelle (102) vs D&C (101)Adequacy\
Pipelle 98%\
D&C 100%Pipelle less painfulPipelle cheaper\[[@CR46]\] Liu et al. China 2015Prospective Sequential43.6Pipelle vs D&C (245)Adequacy\
Pipelle 91.02%\
D&C 92.24%Pipelle less painfulN/A\[[@CR47]\] Gungorduk et al. Turkey 2013ProspectivePipelle: 49.8 ± 6.1\
D&C: 48.2 ± 6.5Pipelle + hysterectomy (78) vs D&C + hysterectomy (189)Adequacy\
Pipelle 95%\
D&C 96%\
Concordance\
Pipelle + hysterectomy 62%\
D&C + hysterectomy 67%Pipelle less painfulPipelle cheaper\[[@CR48]\] Kazandi et al.\
Turkey\
2012Prospective Sequential48 ± 9.43Pipelle + hysterectomy\
Vs\
D&C + hysterectomy\
(66)Adequacy\
Pipelle 93%\
D&C 96%\
Concordance\
Pipelle and D&C 66%\
Pipelle & hysterectomy 64%Pipelle less painfulPipelle cheaper\[[@CR49]\] Demirkiran et al. Turkey 2012Prospective45.3Pipelle + hysterectomy (212) vs D&C + hysterectomy\
(161)Adequacy\
Pipelle 97%\
D&C98%\
Concordance\
Pipelle and D&C 84%\
Pipelle & hysterectomy 67%\
D&C and hysterectomy 80%Pipelle less painfulPipelle cheaper\[[@CR43]\] Sany et al. UK 2011Retrospective?Pipelle + hysterectomy vs D&C + hysterectomy (total 191)Concordance\
Both techniques 78%N/AN/A\[[@CR45]\] Daud et al. UK 2011Retrospective55.7 ± 11.4Pipelle ± hysterectomy (75) vs D&C ± hysterectomy (220)Concordance\
Pipelle + hysterectomy 76%\
D&C + hysterectomy 86%N/AN/A\[[@CR24]\] Fakhar et al. Pakistan 2008Prospective Sequential45.4 ± 7.2Pipelle versus (D&C) (100)Adequacy\
Pipelle 98%\
D&C 100%\
NPV for endometrial carcinoma\
Pipelle 100%N/A (both techniques under GA)Pipelle cheaper\[[@CR44]\] Huang et al. USA 2006Retrospective + Letter?Pipelle + hysterectomy (253) vs D&C + hysterectomy (93)Concordance\
Pipelle and hysterectomy 93.8% (low grade cancer) & 99.2% (high grade cancer)\
D&C and hysterectomy 97% (low grade cancer) & 100% (high grade cancer)N/AN/A\[[@CR37]\] Macones et al. 2006\[[@CR66]\] Machado et al. Spain 2002RetrospectivePost-menopausal (68)\
Pre- or peri-menopausal (100)Pipelle (168) vs D&C (92) ± Hysterectomy (76)Accuracy\
Sensitivity 84.2%\
Specificity 99.1%N/AN/A\[[@CR51]\] Kavak et al. Turkey 1996Prospective50.8 ± 7.8Pipelle ± TVS (78) vs D&C (78)Concordance\
Sensitivity: 73% (increased to 90% with TVS)\
Specificity: 100%N/AN/A\[[@CR50]\] Ben-Baruch et al. Israel 1993ProspectivePre- and post-menopausalPipelle (172) vs D&C (97)Adequacy\
Pipelle 90.6%\
D&C 68%N/AN/A\[[@CR68]\] Sanam et al. Iran 2015Prospective\>  35Pipelle (130) vs D&C (130)Concordance\
Pipelle and D&C 94%\
Adequacy\
Pipelle 84.6%\
D&C 90%N/APipelle cheaper\[[@CR75]\] Gordon New Zealand 1999Prospective47.2 ± 1.8Pipelle (100) vs D&C or hysterectomy (n =?)Adequacy\
Pipelle 67%N/AN/A\[[@CR69]\] Goldchmit et al. Israel 1993Prospective Sequential48.1Pipelle and TVS vs D&C (176)Concordance\
Pipelle & D&C 90% (increased to 92% with TVS)N/AN/A\[[@CR52]\] Abdelazim et al. Turkey 2013Prospective Sequential44.5Pipelle vs D&C (143)Adequacy\
Pipelle 97.9%\
D&C 100%\
NPV for endometrial polyp\
Pipelle 89.6%N/AN/A\[[@CR72]\] Shams Pakistan 2012Prospective Sequential47.94Pipelle vs D&C (50)N/APipelle less painfulPipelle cheaper\[[@CR53]\] Rezk et al. Egypt 2016ProspectivePipelle: 47.2 ± 3.8\
D&C: 46.9 ± 4.1Pipelle (270) vs D&C (268)Adequacy\
No difference (p˃0.05)D&C less painfulN/APipelle versus Vabra +/− Hysterectomy\[[@CR54]\] Eddowes et al. UK 1990Prospective Sequential41.6Pipelle vs Vabra Aspirator (100)Adequacy\
Pipelle 88%\
Vabra Aspirator 88%Pipelle less painfulPipelle cheaper\[[@CR55]\] Naim et al. Malaysia 2007RCT\> 45Pipelle (76) vs Vabra Aspirator (71)Adequacy\
Pipelle 73.3%\
Vabra 52.4%N/APipellle cheaper\[[@CR28]\] Kaunitz et al. USA 1988Prospective Sequential46Pipelle vs Vabra (56)Adequacy\
Pipelle & Vabra 91%\
Concordance\
Pipelle & Vabra 89%Pipelle less painfulPipelle cheaper\[[@CR56]\] Rodriguez et al. USA 1993RCT?Pipelle (12) vs Vabra (13) vs Hysterectomy (25)Surface being sampled:\
Pipelle 4.2%\
Vabra 41.6%N/AN/APipelle versus Tao Brush+/− Hysteroscopy\[[@CR30]\] Williams et al. UK 2008RCT SequentialModerate risk: 45.2 (SE 0.26)For moderate risk Pipelle (34)\
Tao Brush (29)Adequacy\
Both techniques 84%\
No significant difference for premenopausalTao Brush less painfulN/A\[[@CR57]\] Critchley et al. UK 2004RCTModerate risk: pre-menopausal ˃40 or \< 40 with risk for endometrial cancer\
Low riskPipelle vs Tao Brush\
Moderate risk\
(Total 326)\
Low risk (Total 157)\
± hysteroscopy ± TVSSuccessful completion of investigation:\
Pipelle 85%\
Adequacy of sample with Pipelle:\
Moderate risk 79%Tao Brush less painful than PipelleMinimal difference\[[@CR58]\] Yang et al. USA 2003Prospective Sequential24--86Pipelle (79) vs Tao Brush (79)Factors affecting sensitivity: tumour size, type, location within the uterus, sampling mechanism and preparation methodN/AN/A\[[@CR59]\] Del Priore et al. USA 2001RCT SequentialPre-menopausal: 46\
Post-menopausal: 61Tao Brush vs Pipelle (50)Sensitivity:\
Pipelle 86%\
Tao Brush 95.5%\
Specificity:\
Both 100%N/ATao Brush cheaper than D&C\[[@CR60]\] Yang et al. USA 2000Prospective Sequential58Tao Brush vs Tao Brush + Pipelle (25)Adequacy\
Tao Brush 98%\
Pipelle 88%Tao Brush less painfulComparablePipelle versus Novak\[[@CR40]\] Henig et al. USA 1989RCTPre-menopausalPipelle (50) Vs Novak (50)Adequacy\
Pipelle 94%\
Novak 98%Better tolerance with PipelleN/A\[[@CR26]\] Stovall et al. USA 1991RCTPipelle: 40\
Novak: 44Pipelle (149) vs Novak (126)Adequacy\
Pipelle 87.2%\
Novak 90.5%Pipelle less painfulNovak might be cheaper\[[@CR61]\] Silver et al. USA 1991RCT Sequential28--761st Pipelle then Novak (26) vs 1st Novak then Pipelle (29)Adequacy SimilarPipelle less painfulN/APipelle versus Hysterectomy\[[@CR67]\] Guido et al. USA 1995Prospective Sequential61Pipelle vs Hysterectomy\
(71)Adequacy\
Pipelle 97%\
Concordance\
Pipelle & hysterectomy 83%N/AN/A\[[@CR42]\] Ferry et al. UK 1993Prospective Sequential?Pipelle vs Hysterectomy (37)Concordance\
Pipelle & hysterectomy 67%N/AN/A\[[@CR41]\] G Zorlu et al. Turkey 1994Prospective Sequential51Pipelle vs Hysterectomy (26)Concordance\
Pipelle & hysterectomy 95%Mild pain and discomfort with PipelleN/APipelle versus Explora +/− Accurette\[[@CR62]\] Leclair et al. USA 2011RCTPipelle: 45.2 ± 7.3\
Explora: 46.1 ± 7.7Pipelle (37) vs\
Explora (32)Adequacy\
Pipelle 91%\
Explora 97%No differences seenN/A\[[@CR32]\] Lipscomb et al. USA 1994RCTN/A\
Pre- and post-menopausalPipelle (85) vs Accurette (81) vs Explora (82)Adequacy\
Pipelle 85.2%\
Accurette 72.5%\
Explora 85.4%No significant difference in pain scoreN/APipelle versus Infant Feeding Tube (IFT)\[[@CR63]\] Bhide et al. UK 2007Prospective?Pipelle (29) vs IFT (31)Adequacy\
Pipelle 73%\
IFT 71%Less pain with IFTN/APipelle Mark 2 versus Pipelle Mark 2 + hysteroscopy\[[@CR71]\] Polena et al. France 2006Prospective\
Sequential50Pipelle Mark 2 vs Pipelle Mark 2 ± hysteroscopy (97)Adequacy of Pipelle Mark 2\
88.7%No difference with conventional PipelleSlightly more expensive than conventional PipellePipelle versus Tis-u-Trap\[[@CR27]\] Koonings et al. USA 1990RCTPipelle: 42.9\
Tis-u-trap: 42.3Pipelle + hysterectomy (74) vs Tis-u-trap + hysterectomy (75)Adequacy\
Pipelle 87.8%\
Tis-u-trap 84%\
Concordance\
Pipelle & hysterectomy 85%\
Tis-u-trap & hysterectomy 92%N/APipelle cheaperPipelle versus Endorette\[[@CR29]\] Moberger et al. Sweden 1998RCT Sequential57.5 ± 11.5Pipelle vs Endorette\
(152)Adequacy and concordance\
No differenceNo significant differenceN/APipelle versus Cytospat +/− Hysterectomy\[[@CR31]\] Antoni et al. Spain 1996RCT48.6 ± 9Pipelle ± hysterectomy or D&C (191) vs Cytospat ± hysterectomy or D&C (174)Adequacy\
Pipelle 75%\
Cytospat 76%\
Concordance\
Pipelle: Benign 84%, Hyperplasia 71%, Malignancy 60%\
Cytospat: Benign 82%, Hyperplasia 60%, Malignancy 60%Better tolerance for PipellePipelle cheaperPipelle versus D&C +/− Hysteroscopy +/− TV US\[[@CR85]\] Tahir et al. UK 1999RCT35Inpatient: Hysteroscopy & D&C (200) vs Outpatient: Pipelle +/− TV US +/− Hysteroscpy (200)Adequacy\
No difference\
Concordance\
Inpatient: 100&\
Outpatient: 82&More pain in outpatientN/AOthers\[[@CR73]\] Trolice et al. USA 2000RCT Anaesthesia for PipelleLidocaine: 42.1 ± 11.9/ Saline: 44.9 ± 12.5Lidocaine (19) vs Saline (22)Significant reduction of pain with lidocaineLess pain with interventionN/A\[[@CR34]\] Cornier France 1984Brief communicationMostly pre-menopausalPipelle (250)\
No controlUseful for histologic dating of the endometriumLittle discomfortLow cost\[[@CR74]\] Frishman USA 1990Letter in response to study \[[@CR27]\]N/APipelle versus Tis-u-TrapN/AN/APipelle cheaper\[[@CR38]\] Mc Cluggage Northern Ireland 2006ReviewN/APipelle versus other ESDifficulties of processing outpatient ES samplesN/AN/A\[[@CR79]\] Van Den Bosch Belgium 2005Prospective sequentialPre-menopausal: 41.6 ± 8.7\
Post-menopausal: 59 ± 9.9US before and after Pipelle (99)Thickness of the endometrium\
ET on average 0.4 mm less after performing PipelleN/AN/A\[[@CR76]\] Brandner et al. Germany 2000ReviewN/AN/AProgression of endometrial lesions (potential limitations for ES)N/AN/A\[[@CR80]\] Dijkhuizen et al. The Netherlands 2000Meta-analysis39 studies including 7914 patientsDifferent ESPipelle is superior to other ES for diagnosing cancer/ hyperplasiaN/AN/A\[[@CR25]\] Cooper et al. USA 2000ReviewN/AN/ADirected biopsy with Hysteroscopy: most accurate ES (not for primary care)N/AN/A\[[@CR14]\] Farquhar et al. New Zealand 1996Survey68 replies from O&G consultants (48% of all contestants)N/AManagement of menorrhagia in primary careN/AN/A\[[@CR78]\] Youssif et al. Australia 1995ReviewN/AN/AEffectiveness and safety of PipelleN/AN/A\[[@CR77]\] Dantas et al. Brazil 1994LetterNurses vs doctors performing PipelleN/AAdequacy No differenceN/AN/A\[[@CR82]\] Clark et al. UK 2002Systematic review and meta-analysisMixed pre- (21%) and pos-tmenopausal (79%)Pipelle vs other outpatient techniquesLikelihood ratio of endometrial cancer when Pipelle is:\
-ve: 0.1\
+ve: 64.6N/AN/A\[[@CR86]\] Ahonkallio et al. Finland 2009ProspectiveRange 47--52 Post ablationPipelle (57)Adequacy\
29% failure If\
endometrium \< 5 mm\
5% failure if endometrium \> 5 mmN/AN/A\[[@CR81]\] Du et al. China 2016ReviewN/AN/AMost appropriate ES devices for endometrial lesionsLittle discomfortN/A\[[@CR64]\] Masood et al. Pakistan 2015Cross sectionalPre- and post-menopausal 35--48Pipelle (126) vs no comparatorAdequacy\
Pipelle 96.82%N/ACost-effective\[[@CR39]\] Seamark UK 1998Prospective≥40\
42--74\
Primary care populationPipelle (38) vs no comparatorAdequacy\
Pipelle 76%N/AN/A\[70\]Seto UK 2016RetrospectivePre-menopausal 46.1 ± 4.6\
Post-menopausal\
57.2 ± 8.1Pipelle against hysteroscopyPositive predictive value for endometrial polyp\
Pipelle (pre-menopausal) 53.7%N/AN/A\[[@CR65]\] Piatek et al. Poland 2016RetrospectivePre- and post-menopausalPipelle (312) vs no comparatorAdequacy\
83.01%N/AN/A*ES* Endometrial sampling, *AUB* Abnormal uterine bleeding, *RCT* Randomized controlled trials, *US* Transvaginal ultrasound, *N/A* Non-applicable,? Unknown

Sample adequacy {#Sec9}
---------------

Overall, the literature showed that the adequacy of material retrieved for histological analysis with Pipelle was comparable to D&C and superior to most of the other devices in pre-menopausal women. Ten studies \[[@CR23], [@CR24], [@CR46]--[@CR53]\] assessed Pipelle against D&C in premenopausal women, reporting rates of adequacy ranging from 89.74% \[[@CR51]\] to 98% \[[@CR23], [@CR24]\] (Table [1](#Tab1){ref-type="table"}).

Three studies compared the sample adequacy of Pipelle and Vabra Aspirator \[[@CR28], [@CR54], [@CR55]\]. One of these studies \[[@CR55]\] showed better rates for Pipelle (73.3% versus 52.4%, *P =* 0.02) whereas the remaining two could not identify any significant difference between both techniques (one study reported 91% for both techniques \[[@CR28]\] whereas the other showed 89.79% for Vabra versus 88% for Pipelle \[[@CR54]\], no *P* values provided) (Table [1](#Tab1){ref-type="table"}). We also found a RCT which reported that Pipelle despite being equal or superior to Vabra in terms of sample adequacy only assesses 4.2% of the endometrium versus 41.6% with Vabra \[[@CR56]\].

Five studies including mixed cohorts of pre- and postmenopausal women compared sample adequacy between Pipelle and Tao Brush \[[@CR30], [@CR57]--[@CR60]\]. Despite one study suggesting that Tao Brush bendable wire should improve sampling of the uterine lateral walls when compared to Pipelle more rigid structure, none of the studies showed significant differences in premenopausal populations \[[@CR58]\] (Table [1](#Tab1){ref-type="table"}).

Two studies \[[@CR40], [@CR61]\] also compared Pipelle to Novak and found no statistically significant difference in terms of adequacy of sample, which varied from 83 to 94% for Pipelle and from 85 to 98% for Novak \[[@CR40], [@CR61]\] (Table [1](#Tab1){ref-type="table"}). Six additional studies did not find a significant difference when comparing Pipelle with other less popular ES techniques such as Explora \[[@CR32], [@CR62]\] (85.4--97% for Explora versus 85.2--91% for Pipelle), Tis-u-trap \[[@CR27]\] (88% for Pipelle versus 84% for Tis-u-Trap *P =* 0.5), Endorette \[[@CR29]\] (56% for Endorette versus 43% for Pipelle), infant feeding tube \[[@CR63]\] (73% for Pipelle versus 71% for IFT) and Cytospat \[[@CR31]\] (Pipelle 74.9% versus 75.9% for Cytospat).

Three studies \[[@CR39], [@CR64], [@CR65]\] assessed the ability of Pipelle to retrieve enough tissue for histological analysis without comparing it to other devices, and reported a success rate of 76% in GP practices \[[@CR39]\], and a range from 83.01 to 96.82% in secondary care \[[@CR64], [@CR65]\] (Table [1](#Tab1){ref-type="table"}).

Test performance {#Sec10}
----------------

Nine studies compared the histopathological diagnosis of pre-operative Pipelle and D&C with the final results from hysterectomy (the gold standard diagnostic technique for uterine disorders) \[[@CR41], [@CR43]--[@CR45], [@CR47]--[@CR49], [@CR66], [@CR67]\]. For Pipelle, the sensitivity ranged from 62% \[[@CR47]\] to 99.2% \[[@CR44]\] and for D&C sensitivity varied from 67% \[[@CR47]\] to 100% \[[@CR44]\]. One of these studies applied Pipelle and D&C sequentially before hysterectomy \[[@CR48]\], while the rest were multi-arm studies \[[@CR41], [@CR43]--[@CR45], [@CR47], [@CR49], [@CR66], [@CR67]\] (Table [1](#Tab1){ref-type="table"}).

At least 5 studies \[[@CR43], [@CR48], [@CR49], [@CR68], [@CR69]\] also reported on the concordance between Pipelle and D&C with values that ranged from 66% \[[@CR48]\] to 94% \[[@CR68]\].

One retrospective study which compared Pipelle samples suggestive of endometrial polyps with subsequent hysteroscopically-guided polypectomies reported Pipelle had a positive predictive value of 55.3% for sampling polyps in premenopausal women \[[@CR70]\]. Pipelle has also been reported to have 100% negative predictive value (NPV) for endometrial carcinoma and hyperplasia \[[@CR24]\] and up to 99.2% NPV for endometritis and 89.6% for endometrial polyps \[[@CR52]\] (Table [1](#Tab1){ref-type="table"}).

Pain / discomfort {#Sec11}
-----------------

Most studies included in this review performed ES on awake patients, but only 23 studies formally assessed patients' pain using visual pain analogue scales and questionnaires (Table [1](#Tab1){ref-type="table"}). A total of 15 studies reported that most patients experienced minimal discomfort with Pipelle \[[@CR23], [@CR26], [@CR28], [@CR31], [@CR34], [@CR40], [@CR41], [@CR46]--[@CR49], [@CR54], [@CR61], [@CR71], [@CR72]\], three did not find any significant difference between Pipelle and Explora \[[@CR32], [@CR62]\] and Pipelle and Endorette \[[@CR29]\], three concluded that Tao Brush was better tolerated than Pipelle \[[@CR30], [@CR57], [@CR60]\] and one study showed less discomfort when using an infant feeding tube as a prototype \[[@CR63]\]. A RCT also reported that paracervical lidocaine during Pipelle may decrease pain when compared to placebo \[[@CR73]\] (Table [1](#Tab1){ref-type="table"}).

Costs of outpatient endometrial sampling {#Sec12}
----------------------------------------

A total of 17 studies assessed the cost-effectiveness of Pipelle though none formally provided a health economic analysis \[[@CR23], [@CR24], [@CR26]--[@CR28], [@CR31], [@CR47]--[@CR49], [@CR54], [@CR55], [@CR57], [@CR60], [@CR68], [@CR71], [@CR72], [@CR74]\]. Some of the factors they considered when assessing the total cost of ES were the need for general anaesthesia and hospital admission \[[@CR23], [@CR72]\] and the cost of operative hysteroscopy/ D&C following a failed office ES or an inadequate sample \[[@CR55]\]. Fifteen studies showed Pipelle was cheaper than the alternative ES \[[@CR23], [@CR24], [@CR26]--[@CR28], [@CR31], [@CR47]--[@CR49], [@CR54], [@CR55], [@CR57], [@CR68], [@CR72], [@CR74]\] and two did not find significant differences between Pipelle and Pipelle Mark 2 \[[@CR71]\], and Pipelle and Tao Brush \[[@CR60]\]. Two studies concluded that the Vabra was cheaper than Pipelle given its multiple use \[[@CR26]\] but when all costs were considered including the need for follow-up for failed procedures, the average cost of Pipelle per patient was approximately 30% cheaper than the Vabra aspirator \[[@CR55]\] (Table [1](#Tab1){ref-type="table"}).

Barriers and complications to endometrial sampling in primary care {#Sec13}
------------------------------------------------------------------

Several limitations to successful ES were reported including cervical stenosis and pelvic organ prolapse which hindered the access to the uterine cavity \[[@CR24], [@CR75]\] as well as focal endometrial pathology (e.g. endometrial polyps and submucosal fibroids) and endometrial atrophy which reduces sample adequacy \[[@CR30], [@CR46], [@CR69], [@CR75], [@CR76]\]. Lack of experience was also linked to inadequate sampling with higher failure rates seen in registrars (39%) than in consultants (25%), (*P* = 0.13)) \[[@CR75]\]. However, a study which compared sample adequacy between nurses (83.3%) and doctors (80%), *P* \> 0.05, concluded that with the right training the ability to perform successful Pipelle is independent of professional category \[[@CR77]\].

While few complications have been associated with Pipelle \[[@CR73]\]. \[[@CR78]\], mainly discomfort and false negative results, a study showed that Pipelle makes the endometrium approximately 0.4 mm thinner and creates echogenic spots which can be misinterpreted as sonographic lesions if the ultrasound is not performed prior to ES \[[@CR79]\] (Table [1](#Tab1){ref-type="table"}).

Discussion {#Sec14}
==========

Our aim was to search and synthesise the whole range of literature on ES in AUB in low-risk patients to guide further research and develop new evidence-based care pathways in primary care. Overall, the evidence that we have identified supports the use of ES in the outpatient setting and is a valuable source for the development of new care pathways in primary care.

To the best of our knowledge, this study is the first systematic review to primarily focus on the role of ES in assessing and managing AUB in low-risk women in the outpatient setting \[[@CR25], [@CR78], [@CR80]--[@CR82]\]. The available evidence shows that when Pipelle is combined with clinical assessment and ultrasound findings, it becomes a valuable tool for investigating AUB in low-risk women. Pipelle seems to perform as well or better than any other ES device in terms of sampling adequacy and sensitivity, with comparable results to D&C which for years was the standard technique for obtaining endometrial tissue in patients with AUB \[[@CR78]\]. Furthermore, Pipelle seems to be cost-effective and better tolerated in terms of pain/discomfort \[[@CR83]\]. However, its use has shown to be limited by cervical stenosis, pelvic organ prolapse and endometrial atrophy \[[@CR24], [@CR75]\]. Since Pipelle causes changes in the endometrium, it should not be performed before USS \[[@CR79]\], and if the ultrasound reports localised lesions, a hospital referral for a hysteroscopy-guided biopsy may prove more useful than performing a blind Pipelle \[[@CR84]\] given its limited sensitivity for focal lesions \[[@CR47], [@CR70]\].

Despite our robust and thorough literature search, we have noted some limitations in the available evidence. We only identified one study which was conducted on a primary care population by general practitioners \[[@CR39]\] and one study which looked exclusively at premenopausal patients \[[@CR40]\] and therefore, our conclusions are mainly based on studies which were carried out in either outpatient specialised clinics or hospital departments on a mixed cohort of pre- and postmenopausal women. Many of the studies that we identified were of poor or moderate methodological quality with wide-ranging inclusion and exclusion criteria (see Additional file [2](#MOESM2){ref-type="media"}). This heterogeneity may partly be responsible for the significant variability seen in terms of the sensitivity and specificity of Pipelle for detecting endometrial hyperplasia/cancer.

A meta-analysis was beyond the scope of this paper but critical appraisal and analysis of pooled data from diagnostic studies is an important next step in establishing the utility of ES. Given the limited information about the true test performance of ES in the community, it is not possible for clinicians to quantify the risk of hyperplasia/cancer (or other pathology) based only on ES. This is especially pertinent when the sample result is normal but the patient is still symptomatic; clinicians should then continue to consider the possibility of false negative results e.g. undiagnosed cancer/hyperplasia in these patients.

Conclusions {#Sec15}
===========

The evidence we analysed suggests that performing ES in the outpatient setting may allow effective management of low-risk women with AUB in primary care without referral to a hospital. But the false negative rate, health economics and implications of such a change in practice are still unknown and more research is required.
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Additional file 1:Literature search strategy. Search strategies and key words employed in the literature review. (DOCX 11 kb). Additional file 2:Study quality assessment. Assessment of methodological quality of the studies included in the literature review. (DOCX 62 kb).

AUB

:   Abnormal uterine bleeding

D&C

:   Dilation and curettage

ES

:   Endometrial sampling

PMB

:   Postmenopausal bleeding

RCT

:   Randomised controlled trial

USS

:   Ultrasound scan
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